Trombolitik Tedavi Yaşlı Hastalarda Etkili mi? Kanama?

Dünya çapında nüfus artmakta olduğu için varolan ST segment yükselmeli akut miyokardiyal infarktüsü (AMI) olan yaşlı hasta sayısı da artmaktadır. Trombolitik tedavi (TT) ST segment yükselmeli akut miyokard infarktüsü olan ve 75 yaşından büyük olmayan hastalara uygulanır. Yaşlı hastalara perkutan transluminal koroner anjiyoplasti (PTCA) veya baypas ameliyatı uygulaması önerilir. Perkutan transluminal koroner anjiyoplasti veya baypas ameliyatı için büyük hastanelerde bulunabilen hazırlıklı bir kardiyo-cerrahi ekibi gereklidir. Yetmiş beş yaş üzeri ST segment yükselmeli akut miyokard infarktüsü olan hiç TT uygulanmamış hastaların, yaşam uzunlukları ve kalitelerini tahmin etmek şüphelidir. Trombolitik tedavi istenen etkilerinin yanı sıra büyük (ölümcül) veya küçük kanama gibi istenmeyen etkilere neden olabilir.

Is Thrombolytic Therapy Effective in Elderly Patients? Bleeding?

As the population increases worldwide, the number of elderly patients who present with acute myocardial infarction (AMI) with ST-segment elevation will continue to grow. Thrombolytic therapy (TT) is applied in patients with AMI with ST-segment elevation and aged no more than 75 years. It is recommended percutaneous transluminal coronary angioplasty (PTCA) or by-pass surgery to elderly patients. For PTCA and by-pass surgery there has to be a prepared cardio-surgery medical team, which can be found in big medical hospitals. Patients with AMI with ST-segment elevation over 75 years, which has no TT applied, are with suspicious prognosis for longevity and quality of life. Along with its needed effects TT may cause some unwanted effects such as incidence of major (fatal) or minor bleeding. Dünya çapında nüfus artmakta olduğu için varolan ST segment yükselmeli akut miyokardiyal infarktüsü (AMI) olan yaşlı hasta sayısı da artmaktadır. Trombolitik tedavi (TT) ST segment yükselmeli akut miyokard infarktüsü olan ve 75 yaşından büyük olmayan hastalara uygulanır. Yaşlı hastalara perkutan transluminal koroner anjiyoplasti (PTCA) veya baypas ameliyatı uygulaması önerilir. Perkutan transluminal koroner anjiyoplasti veya baypas ameliyatı için büyük hastanelerde bulunabilen hazırlıklı bir kardiyo-cerrahi ekibi gereklidir. Yetmiş beş yaş üzeri ST segment yükselmeli akut miyokard infarktüsü olan hiç TT uygulanmamış hastaların, yaşam uzunlukları ve kalitelerini tahmin etmek şüphelidir. Trombolitik tedavi istenen etkilerinin yanı sıra büyük (ölümcül) veya küçük kanama gibi istenmeyen etkilere neden olabilir.

___

  • Moriel M, Behar S, Tzivoni D, Hod H, Boyko V, Gottlieb S. Management and outcomes of elderly women and men with acute coronary syndromes in 2000 and 2002. Arch Intern Med 2005;165:1521-6.
  • A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997;337:1118-23.
  • Buiatti E, Barchielli A, Marchionni N, Balzi D, Carrabba N, Valente S, et al. Determinants of treatment strategies and survival in acute myocardial infarction: a population-based study in the Florence district, Italy: results of the acute myocardial infarction Florence registry (AMI-Florence). Eur Heart J 2003;24:1195-203.
  • Selker HP, Beshansky JR, Griffith JL; TPI Trial Investigators. Use of the electrocardiograph-based thrombolytic predictive instrument to assist thrombolytic and reperfusion therapy for acute myocardial infarction. A multicenter, randomized, controlled, clinical effectiveness trial. Ann Intern Med 2002;137:87-95.
  • White HD. Debate: Should the elderly receive thrombolytic therapy or primary angioplasty? Curr Control Trials Cardiovasc Med 2000;1:150-4.
  • Krumholz HM, Murillo JE, Chen J, Vaccarino V, Radford MJ, Ellerbeck EF, et al. Thrombolytic therapy for eligible elderly patients with acute myocardial infarction. JAMA 1997;277:1683-8.
  • Topol EJ; GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.
  • White HD. Thrombolytic therapy in the elderly. Lancet 2000;356:2028-30.
  • Brass LM, Lichtman JH, Wang Y, Gurwitz JH, Radford MJ, Krumholz HM. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: results from the Cooperative Cardiovascular Project. Stroke 2000;31:1802-11.
  • Lichtman JH, Krumholz HM, Wang Y, Radford MJ, Brass LM. Risk and predictors of stroke after myocardial infarction among the elderly: results from the Cooperative Cardiovascular Project. Circulation 2002;105:1082-7.
  • Väisänen O, Mäkijärvi M, Silfvast T. Quality of life of elderly patients after prehospital thrombolytic therapy. Resuscitation 2005;66:183-8.
  • Taneva E. Is thrombolytic therapy effective in elderly patients? Rejuvenation Res 2006;9:358-61.
  • Rich MW. Thrombolytic therapy is indicated for patients over 75 years of age with st-elevation acute myocardial infarction: protagonist viewpoint. Am J Geriatr Cardiol 2003;12:344-7.
  • Weil A. Western herbal medicine: nature's green pharmacy. In: Pelletier KR, editor. The best alternative medicine. 1st ed. New York: Simon and Schuster; 2002. p. 152-77.
  • Martínez-Sellés M, López-Palop R, Pérez-David E, Bueno H. Influence of age on gender differences in the management of acute inferior or posterior myocardial infarction. Chest 2005;128:792-7.